Skip to main content

Table 2 Demographic characteristics in the total vaccinated cohort

From: Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial

 

AS03C

AS03C-MPL25

AS03C-MPL50

AS03B

AS03B-MPL25

AS03B-MPL50

AS03A

AS03A-MPL25

Non-adjuvanted ≥65 years

Non-adjuvanted 18–40 years

 

N=204

N=202

N=198

N=202

N=199

N=199

N=202

N=198

N=200

N=203

Age at vaccination (years)

 Mean±SD

72.7±5.75

72.9±6.09

72.6±5.67

72.6±5.16

72.5±5.66

73.0±6.03

72.4±5.62

72.7±5.56

72.7±5.43

27.4±6.25

 Median (min–max)

72.0

71.0

72.0

72.0

72.0

72.0

71.0

72.0

72.0

27.0

(63–91)

(64–91)

(65–94)

(65–87)

(65–91)

(62–95)

(65–90)

(65–88)

(65–89)

(18–40)

Gender, n (%)

 Female

95 (46.6)

100 (49.5)

96 (48.5)

109 (54.0)

89 (44.7)

95 (47.7)

105 (52.0)

102 (51.5)

90 (45.0)

103 (50.7)

 Male

109 (54.3)

102 (50.5)

102 (51.5)

93 (46.0)

110 (55.3)

104 (52.3)

97 (48.0)

96 (48.5)

110 (55.0)

100 (49.3)

Geographic Ancestry, n (%)

 African/African American

1 (0.5)

0

2 (1.0)

0

0

1 (0.5)

0

1 (0.5)

0

2 (1.0)

 Asian–Central/South

1 (0.5)

0

0

0

0

0

0

0

0

0

 Asian–South East

1 (0.5)

1 (0.5)

2 (1.0)

0

0

1 (0.5)

2 (1.0)

0

0

0

 White–Arabic/North African

2 (1.0)

1 (0.5)

1 (0.5)

1 (0.5)

1 (0.5)

1 (0.5)

0

3 (1.5)

0

2 (1.0)

 White–Caucasian/European

199 (97.5)

199 (98.5)

193 (97.5)

201 (99.5)

197 (99.0)

195 (98.0)

198 (98.0)

194 (98.0)

200 (100.0)

197 (97.0)

 Other

0

1 (0.5)

0

0

1 (0.5)

1 (0.5)

2 (1.0)

0

0

2 (1.0)

  1. TVC, total vaccinated cohort; All participants received inactivated trivalent influenza vaccine, non-adjuvanted (≥65 years and 18–40 years) or formulated with an adjuvant. AS03 is a squalene and α-tocopherol oil-in-water emulsion-based Adjuvant System, with tocopherol content 11.86 mg (A), 5.93 mg (B), or 2.97 mg (C); MPL is 3-O-desacyl-4’- monophosphoryl lipid A: 25 μg (MPL-25) or 50 μg (MPL-50).